CG
PRTK

Carlyle Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Carlyle Group’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,041,131
Closed -$2.3M – 27
2023
Q2 		$2.3M Hold
1,041,131
– – 0.08% 22
2023
Q1 		$2.62M Buy
+1,041,131
New +$2.06M 0.08% 22

Carlyle Group's PRTK Position: Q3 2023 in Review

Carlyle Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 1,041,131 shares — an estimated $2.3M sold.

Carlyle Group first reported a position in PRTK in Q1 2023 and held it in 2 quarters. The position peaked at $2.62M in Q1 2023. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

  • Carlyle Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Carlyle Group sold 1,041,131 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $2.3M.
  • Carlyle Group first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2023 and held it in 2 quarters.
  • Carlyle Group's Paratek Pharmaceuticals, Inc. position peaked at $2.62M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on Carlyle Group's 13F filing for Q3 2023, filed 3 Nov 2023.